Research
Energy balance
73.9% of participants in the 4-mg mazdutide group achieved a weight reduction of at least 5% at week 32.
A significant proportion of adults with obesity or overweight may benefit from mazdutide treatment.
StrongSupportsmedium confidence
73.9%, 82.0%, and 10.5% of the participants, respectively, had a weight reduction of at least 5% (P<0.001 for all comparisons with placebo).
Why this rating
Based on a phase 3, double-blind, placebo-controlled trial.
Source
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
Linong Ji et al. · New England Journal of Medicine · 2025
rct · n=610Cited 64×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →